Division of Pfizer Inc.
Latest From Hospira Inc.
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.
The past decade has been transformative for the global biosimilars industry as regulators, developers, physicians, patients and payers from all over the world have grappled with complex, and often market-shaping, issues.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
The launch of injectable doxercalciferol and FDA approvals for mycophenolic acid delayed-release tablets and betamethasone dipropionate ointment could add some cheer to Lupin whose high-potential launches in the US have seen delays. However, analysts are not very enthused.
- Diagnostic Imaging Equipment & Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Drug Delivery
- Generic Drugs
- Therapeutic Areas
- Hospital Products Division (Abbott)
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
F. Michael Ball, CEO
Thomas E Werner, SVP, Fin. & CFO
Sumant Ramachandra, PhD, SVP, CSO
Marc Yoskowitz, SVP, Strategy & Corp. Dev.
- Contact Info
Phone: (224) 212-2000
275 N. Field Dr.
Lake Forest, IL 60045
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.